R

Red Osmo | Oncologico Potosino

Research site
(Unclaimed)
Location
La Mora 139 Fraccionamiento del Parque, San Luis Potosi, San Luis Potosi, Mexico
Site insights

Top conditions

Lung Cancer (1 trial)

Uterine Cervical Cancer (1 trial)

Urinary Bladder Cancer (1 trial)

Non-Small-Cell Lung Carcinoma (1 trial)

Top treatments

Tisotumab
Gemcitabine
TAR-200
Cisplatin
Pembrolizumab

Parent organization

This site is a part of Red Osmo

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

3 of 3
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Enrolling
Urinary Bladder Neoplasms
Drug: TAR-200
Radiation: Conventional radiation therapy

This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Carboplatin
Drug: Paclitaxel
Recently updated

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cer...

Enrolling
Cervical Cancer
Drug: tisotumab vedotin
Drug: gemcitabine

Trial sponsors

Arcus Biosciences logo

Arcus Biosciences (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems